Becton Dickinson and Co (NYSE:BDX) – Equities researchers at Svb Leerink increased their Q3 2019 earnings per share (EPS) estimates for Becton Dickinson and in a research report issued on Wednesday, July 10th. Svb Leerink analyst R. Newitter now anticipates that the medical instruments supplier will post earnings per share of $3.07 for the quarter, up from their prior forecast of $3.03.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The firm had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. During the same period in the previous year, the company earned $2.65 earnings per share. The firm’s quarterly revenue was down .6% on a year-over-year basis.
Several other research analysts have also recently weighed in on BDX. BMO Capital Markets boosted their price objective on shares of Sun Life Financial from C$58.00 to C$60.00 in a report on Friday, May 10th. Barclays cut shares of Buckeye Partners from an “overweight” rating to an “equal weight” rating in a report on Monday, May 13th. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Wells Fargo & Co reduced their target price on shares of Nevro from $75.00 to $70.00 and set an “outperform” rating for the company in a report on Monday, May 13th. Finally, KeyCorp upped their target price on shares of Harsco from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Friday, May 10th. Five analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $262.67.
BDX opened at $252.88 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. The firm’s 50 day moving average is $243.07. Becton Dickinson and has a twelve month low of $208.62 and a twelve month high of $265.87. The stock has a market capitalization of $69.10 billion, a PE ratio of 22.97, a price-to-earnings-growth ratio of 1.90 and a beta of 1.12.
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 7th were paid a $0.77 dividend. The ex-dividend date was Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.22%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.
In other news, EVP Patrick Kaltenbach sold 191 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $241.03, for a total value of $46,036.73. Following the completion of the sale, the executive vice president now directly owns 19,072 shares of the company’s stock, valued at $4,596,924.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Simon D. Campion sold 2,903 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total transaction of $687,836.82. Following the completion of the sale, the executive vice president now directly owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,154 shares of company stock valued at $4,955,775. Corporate insiders own 0.12% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC increased its stake in shares of Becton Dickinson and by 5.0% in the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after purchasing an additional 842,590 shares in the last quarter. Ronna Sue Cohen boosted its position in shares of Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after acquiring an additional 5,710,365 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after acquiring an additional 416,459 shares during the last quarter. Fundsmith LLP boosted its position in shares of Becton Dickinson and by 0.9% during the first quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock worth $941,772,000 after acquiring an additional 35,453 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of Becton Dickinson and by 0.7% during the first quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock worth $805,082,000 after acquiring an additional 23,645 shares during the last quarter. 84.54% of the stock is owned by hedge funds and other institutional investors.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Why is the price target of stocks important?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.